Bayer’s Virtual AGM: Shareholder Frustration and a Focus on Crop Science Innovation

Bayer’s recent virtual Annual General Meeting (AGM) was marked by significant shareholder frustration regarding the ongoing Roundup litigation in the United States and the repercussions of its contentious 2016 acquisition of Monsanto. Although investors recognized the operational improvements implemented by CEO Bill Anderson, many emphasized that trust in the company has yet to be regained.

Institutional shareholders voiced concerns over a decade of sustained underperformance, pointing out that Bayer’s stock has notably underperformed relative to the DAX index since the Monsanto acquisition. In response, Anderson assured investors that Bayer has made “great progress” in its turnaround efforts and legal strategies, but he acknowledged, “the work isn’t complete. Yet.”

Crop Science: Transitioning to “Delivery Mode”

In light of increasing regulatory pressure and shrinking profit margins, the Crop Science division has emerged as a crucial component of Bayer’s turnaround strategy. Anderson confirmed that the division has initiated a five-year plan aimed at enhancing competitiveness, accelerating innovation, and improving cash flow. The emphasis for 2025 and 2026 will be on execution rather than expansion.

“We kicked off an extensive performance improvement program, focusing on delivery,” said Anderson, mentioning the challenging decisions required to streamline Bayer’s portfolio and global operations. This strategy represents a shift from traditional volume-driven chemistry towards more differentiated, higher-margin crop protection technologies, advocating fewer but stronger product initiatives.

Plenexos and Precision Chemistry Take the Spotlight

A pivotal takeaway from the AGM was Bayer’s ongoing commitment to developing next-generation insecticides that prioritize precision, sustainability, and regulatory compliance. Anderson highlighted Plenexos, a new insecticide that debuted in Colombia at the end of 2025, with plans to launch in Brazil in 2026, pending regulatory approval. This product can be applied at gram-scale rates per acre, showcasing Bayer’s commitment to effective chemistry while reducing its environmental impact.

Now Read: Litigation Exposure Constrains Risk-Taking Among Major Seed Companies – SOSV’s Po Bronson

“If the soccer pitch at the BayArena were a soybean field, you could treat it with only 17 grams of Plenexos,” Anderson remarked, highlighting Bayer’s argument to regulators and investors that modern crop protection does not necessitate blanket applications.

Innovation Pipeline Positioned for Post-2027 Impact

While immediate results may be hindered by regulatory challenges, Bayer clarified that its most groundbreaking agricultural innovations are anticipated to emerge beyond 2027. Key developments include PRECEON™ short corn, touted for its low carbon footprint, and Icafolin, which is considered the first significant new herbicide mode of action in a generation.

These innovations underscore Bayer’s heavy investment in research and development and highlight the importance of regulatory certainty in fostering continued advancements in crop protection technology.

Glyphosate Litigation as an Innovation Risk

In discussions with financial analysts focusing on balance-sheet implications, Anderson framed the Roundup litigation as a distinct risk to future innovation in agriculture. As the U.S. Supreme Court prepares to consider Bayer’s glyphosate case, Anderson cautioned that ongoing litigation could discourage investment in long-term agricultural technologies.

“Why continue that work if it still leaves you at the mercy of a $600 billion litigation industry?” he asked, emphasizing the broader implications for future crop protection and seed technology advancements.

Pointing to recent legislative advancements in states like Kentucky, he indicated a growing political support base for protecting farmers’ access to federally regulated crop protection tools. “We’re thankful to see a broad coalition of farmers, farmer groups, and the scientifically-minded public calling on lawmakers in other states to follow suit,” he stated.

Capital Discipline Tightens Around Crop Science

Shareholders also voted to accept Bayer’s proposal to pay the minimum legally required dividend, reinforcing the company’s commitment to cash generation and debt reduction as essential priorities.

For the Crop Science division, this translates to increased pressure to self-fund innovations, less tolerance for underperforming assets, and ongoing scrutiny of regional and product-line profitability.

Now Read: “The Great Unbundling of Ag” Could Accelerate Innovation – Leaps by Bayer’s Derek Norman

Anderson characterized 2026 as a year aimed at fortifying operational foundations, with the intent to accelerate innovation once margins and cash flow improve.

Despite waning patience from investors, Bayer is banking on the potential of a streamlined Crop Science division, centered around precision products and long-term biological and genetic advancements, to deliver growth in a more stable environment once litigation uncertainties are resolved.